Imipramine

證據等級: L5

預測適應症: 7 個

Imipramine: From Depression to Attention-Deficit/Hyperactivity Disorder

One-Sentence Summary

Imipramine is a classic tricyclic antidepressant (TCA), historically established for the treatment of major depressive disorder. The TxGNN model predicts it may be effective for Attention-Deficit/Hyperactivity Disorder (ADHD), with 1 clinical trial and 20 publications currently associated with this direction — though most of the literature predates modern RCT standards.

Quick Overview

Item	Content
Original Indication	Major Depressive Disorder (based on imipramine’s established TCA classification; no original-indication or license data was returned in this Evidence Pack)
Predicted New Indication	Attention-Deficit/Hyperactivity Disorder
TxGNN Prediction Score	99.90%
Evidence Level	L3
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for this candidate. Based on known pharmacological classification, imipramine is a tricyclic antidepressant (TCA) that inhibits reuptake of norepinephrine and, to a lesser extent, serotonin at the synapse; its efficacy in major depressive disorder is well established, and mechanistically it may be applicable to ADHD through modulation of prefrontal noradrenergic/dopaminergic signaling.

ADHD pathophysiology is linked to dysregulated catecholamine (norepinephrine/dopamine) signaling in the prefrontal cortex — the same system TCAs act on. Before the approval of atomoxetine (a selective norepinephrine reuptake inhibitor), imipramine and desipramine were used clinically as second-line, non-stimulant options for ADHD, particularly in children who did not respond to stimulants such as methylphenidate.

The literature base supporting this link is largely historical (1980s–2000s), consisting of small clinical studies, EEG/P300 biomarker studies, and narrative reviews rather than modern randomized controlled trials. This supports a plausible mechanistic rationale but not a current, high-confidence efficacy signal.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03220308	NA	Completed	103	Tested an 8-week mindfulness training program (plus parallel mindful parenting) vs. care-as-usual in children with ADHD. This is a behavioral intervention trial and does not test imipramine directly (relevance grade C — low direct relevance to the drug).

No clinical trial in this Evidence Pack directly evaluates imipramine for ADHD.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
9465283	1996	Cohort	Clinical EEG (electroencephalography)	In stimulant (pemoline) poor-responders with ADHD, prolonged P300 latency predicted poor response to subsequent imipramine treatment.
18304665	2008	Cohort	Int J Psychophysiology	Imipramine’s effect on EEG in stimulant-non-responsive children with ADHD; imipramine is described as a widely used option when stimulants fail.
6849467	1983	Clinical study	American Journal of Psychiatry	Early report titled “Imipramine for attention deficit disorder” (abstract not available).
15794722	2005	Review	Expert Opinion on Drug Safety	Reviews non-stimulant ADHD treatments; notes tricyclics including desipramine/imipramine as second-line options after atomoxetine.
17078784	2006	Cohort	Expert Rev Neurotherapeutics	Discusses norepinephrine reuptake inhibitors (desipramine, imipramine) alongside atomoxetine as ADHD treatment options, using P300 topography to guide treatment choice.
31776871	2019	Review	CNS Drugs	Systematic review of clinically significant drug-drug interactions for ADHD pharmacotherapy agents.
1974836	1990	Review	Clinical Pharmacy	General review of ADHD epidemiology, diagnosis, and pharmacotherapy.
10790990	1999	Review	Evidence Report/Technology Assessment	Evidence assessment of pharmacological and non-pharmacological ADHD interventions in children and adults.
32982805	2020	Meta-review	Frontiers in Psychiatry	Meta-review of antidepressant efficacy/tolerability/suicidality in children and adolescents, including ADHD as one of several indications assessed.
25295451	2014	Review	Einstein (São Paulo)	General review evaluating therapeutic regimens for ADHD.

10 additional lower-tier records (case-level platelet-binding pharmacology studies, drug-interaction case notes, and comorbidity reviews) are available in the Evidence Pack but are omitted here as lower priority.

US Market Information

No marketing authorizations are on file for this candidate in the current dataset — taiwan_regulatory.total_licenses = 0 and market status is recorded as Not Marketed. No NDA number, product name, or approved indication text is available to report.

Safety Considerations

Please refer to the package insert for safety information. No key warnings, contraindications, or drug-drug interaction data were returned for this candidate (DDI query status: not found).

Note: TFDA/FDA label warnings and contraindications are flagged as a Blocking data gap (DG001) in this Evidence Pack — this must be resolved before any safety pre-assessment (S1) can proceed.

Conclusion and Next Steps

Decision: Hold

Rationale: The drug currently has no marketing authorization on file (0 licenses), label-level safety data is a Blocking gap that prevents safety pre-screening, and the ADHD evidence base (L3) consists almost entirely of retrospective/cohort studies and narrative reviews from the 1980s–2000s rather than modern controlled trials. The signal is mechanistically plausible but not yet actionable.

To proceed, the following is needed:

TFDA/FDA package insert warnings and contraindications (Blocking gap DG001)
Confirmed mechanism of action / pharmacology detail (High-priority gap DG002)
Modern RCT or systematic review data specifically evaluating imipramine (or TCA class) for ADHD
Completed drug-drug interaction database query (currently not_found)
Clarification of current US marketing/regulatory status if a repurposing pathway is to be pursued
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.